TELA Bio（NASDAQ:TELA）报告称，第四季度每股亏损$0.23，低于分析师预期的$0.22，低于预期4.55%。与去年同期每股亏损$0.53相比，这是亏损减少56.6%。公司报告的季度销售额为$1764.9万，低于分析师预期的$2316.6万，低于预期23.82%。相比去年同期的$1699.8万，销售额增长了3.83%。

TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 56.6 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $17.649 million which missed the analyst consensus estimate of $23.166 million by 23.82 percent. This is a 3.83 percent increase over sales of $16.998 million the same period last year.